Related Experiment Videos
Some factors affecting phencyclidine biotransformation by human liver and placenta
R Pohorecki1, W Rayburn, W W Coon
1Department of Pharmacology, University of Michigan, Ann Arbor 48109-0626.
Summary
Human liver and placenta microsomes metabolize phencyclidine (PCP) in vitro. Liver microsomes showed higher hydroxylation activity than placental microsomes, with variations observed between individuals and influenced by smoking and disease stage.
Area of Science:
- Pharmacology
- Biochemistry
- Toxicology
Background:
- Microsomes are key cellular components involved in drug metabolism.
- Phencyclidine (PCP) is a substrate used to study hydroxylation pathways.
- Liver and placenta microsomes exhibit distinct metabolic profiles.
Purpose of the Study:
- To investigate the in vitro hydroxylation of phencyclidine (PCP) by human liver and placenta microsomes.
- To compare the hydroxylation capabilities of liver versus placenta microsomes.
- To identify factors influencing PCP metabolism, such as smoking and disease stage.
Main Methods:
- Human liver and placenta microsomes were isolated.
- In vitro hydroxylation assays were performed using PCP as the substrate.
- Quantification of three hydroxylated PCP metabolites: 3-OH-cyclo-PCP, 4-OH-cyclo-PCP, and 4-OH-pip-PCP.
Main Results:
- Significant inter-individual variability in PCP hydroxylation was observed in both liver and placenta samples.
- Liver microsomes demonstrated higher hydroxylation efficiency compared to placenta microsomes.
- PCP hydroxylation to 3-OH-cyclo-PCP was enhanced in tobacco smokers' liver samples.
- Liver hydroxylation of 4-OH-cyclo-PCP showed a negative correlation with the stage of Hodgkin's disease.
Conclusions:
- Human liver and placenta microsomes possess in vitro hydroxylation capabilities for PCP.
- Liver microsomes are more effective in PCP hydroxylation than placental microsomes.
- Factors like tobacco smoking and disease progression can modulate hepatic PCP metabolism.